Compare · BIOC vs HUM
BIOC vs HUM
Side-by-side comparison of Biocept Inc. (BIOC) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOC and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $42.74B, about 939.9x BIOC ($45.5M).
- HUM has hit the wire 4 times in the past 4 weeks while BIOC has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 0 for BIOC).
- Company
- Biocept Inc.
- Humana Inc.
- Price
- $0.41-20.43%
- $355.91+1.64%
- Market cap
- $45.5M
- $42.74B
- 1M return
- -
- +43.90%
- 1Y return
- -
- +52.72%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
Biocept Inc.
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BIOC
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Biocept Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Netflix Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Latest HUM
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
- President & CEO Rechtin James A. was granted 35,633 units of Humana Common (SEC Form 4)